Posted by Michael Wonder on 05 Apr 2022
European Commission approves Kimmtrak (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
4 April 2022 - Kimmtrak demonstrated statistically and clinically meaningful overall survival benefit, hazard ratio of 0.51, with median overall survival of almost 22 months.
Immunocore today announces that the European Commission has approved Kimmtrak (tebentafusp) for the treatment of HLA-A*02:01 positive adult patients with unresectable or metastatic uveal melanoma.
